drugset / Trial / NCT06059547
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Non-randomizedParallel-groupSingle-blindTreatment
Summary
This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical Cystectomy (RC)/Re-TURBT who cannot receive or refuse to receive cisplatin-based chemotherapy.
Timeline
- Start
- 2023-09-06
- Primary completion
- 2025-10-16
- Completion
- 2026-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Visugromab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |